An observational study in Gonococcal (GC) Infection and Arthritis, Infectious, sponsored by University Hospital, Brest. Recruiting at 2 sites in France. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by University Hospital, Brest · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this retrospective observational study was to describe the epidemiology of Neisseria gonorrhoeae septic arthritis over the last 10 years at Brest and Rennes university hospitals. The main question is whether there are any risk factors based on the epidemiological and clinical data on these cases. The second objective is to characterize the gonococcal strains isolated in order to determine whether there is a common clone, a virulence factor or specific resistance genes.
168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.
This study's planned enrollment of 11 is below the median of 500 across 39 observational studies indexed under Gonorrhea.
Browse Gonorrhea studies →University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with a Neisseria gonorrhoeae-positive joint sample (from an enrichment vial or a native sample) between 06/01/2014 and 06/30/2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a positive joint sample for Neisseria gonorrhoeae between 06/01/2014 and 06/30/2024 in Brittany, France.
Age
years
Time frame: 10 years
Date of sampling
DD/MM/YYYY
Time frame: 10 years
Type of sample
joint fluid or joint fluid on blood culture bottle
Time frame: 10 years
Rate of white blood cells
quantification of white blood cells /mm3
Time frame: 10 years
Sexually transmitted infection
associated or not, if associated, name of STI and localization
Time frame: 10 years
Men who have sex with men
yes or no
Time frame: 10 years
HIV pre-exposure prophylaxis (PreP)
yes or no
Time frame: 10 years
Comorbidities
any history mentioned in the medical file, such as fracture, illness, treatment, chronic alcoholism, cancer, diabetes, etc.
Time frame: 10 years
Imaging
medical conclusion of the ultrasound or radiology performed
Time frame: 10 years
Blood cultures (peripheral blood)
positive or negative
Time frame: 10 years
Time to diagnosis
in days (between onset of symptoms and antibiotics)
Time frame: 10 years
Treatments implemented
name of the probabilistic treatment (antibiotic) and after identification or antibiogram
Time frame: 10 years
Antibiotic sensitivity profile
Susceptibility or resistance according to SIR methodology and, if achieved: minimum inhibitory concentrations of antibiotics tested on the strain in mg/L
Time frame: 10 years
Surgery
yes or not
Time frame: 10 years
Evolution
recovery or relapse
Time frame: 10 years
Rate of neutrophils
proportion of neutrophils in %.
Time frame: 10 years
Rate of CRP (C-reactive protein)
in mg/L
Time frame: 10 years
Molecular typing: clone
performed on strains sent to the Centre National de Référence des IST - APHP
Time frame: 10 years
Molecular typing: virulence factors
performed on strains sent to the Centre National de Référence des IST - APHP
Time frame: 10 years
Molecular typing: resistance genes
performed on strains sent to the Centre National de Référence des IST - APHP
Time frame: 10 years
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
Time frame: Data will be available beginning three years and ending fifteen years following the final study report completion
Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Apr 2025, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.